RT Journal Article
SR Electronic
T1 Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20121558
DO 10.1101/2020.06.03.20121558
A1 Rhodes, Nathaniel J.
A1 Dairem, Atheer
A1 Moore, William J.
A1 Shah, Anooj
A1 Postelnick, Michael J.
A1 Badowski, Melissa E.
A1 Michienzi, Sarah M.
A1 Borkowski, Jaime L.
A1 Polisetty, Radhika S.
A1 Fong, Karen
A1 Spivak, Emily S.
A1 Beardsley, James R.
A1 Hale, Cory M.
A1 Pallotta, Andrea M.
A1 Srinivas, Pavithra
A1 Schulz, Lucas T.
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/06/06/2020.06.03.20121558.abstract
AB Background There are currently no FDA-approved medications for the treatment of COVID-19. At the onset of the pandemic, off-label medication use was supported by limited or no clinical data. We sought to characterize experimental COVID-19 therapies and identify safety signals during this period.Methods We conducted a non-interventional, multicenter, point prevalence study of patients hospitalized with suspected/confirmed COVID-19. Clinical and treatment characteristics within a 24-hour window were evaluated in a random sample of up to 30 patients per site. The primary objective was to describe COVID-19 targeted therapies. The secondary objective was to describe adverse drug reactions (ADRs).Results A total of 352 patients from 15 US hospitals were included. Most patients were treated at academic medical centers (53.4%) or community hospitals (42.6%). Sixty-seven patients (19%) were receiving drug therapy in addition to supportive care. Drug therapies included hydroxychloroquine (69%), remdesivir (10%), and interleukin-6 inhibitors (9%). Five patients (7.5%) were receiving combination therapy. Patients with a history of asthma (14.9% vs. 7%, p = 0.037) and those enrolled in clinical trials (26.9% vs.3.2%, p< 0.001) were more likely to receive therapy. Among those receiving COVID-19 therapy, eight patients (12%) experienced an ADR, and ADRs were more commonly recognized in patients enrolled in clinical trials (62.5% vs 22%, OR = 5.9, p = 0.028).Conclusions While we observed high rates of supportive care for patients with COVID-19, we also found that ADRs were common among patients receiving drug therapy including in clinical trials. Comprehensive systems are needed to identify and mitigate ADRs associated with experimental COVID-19 therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. This study was completed as part of our normal work. REDCap is supported at FSM by the Northwestern University Clinical and Translational Science (NUCATS) Institute. Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number UL1TR001422. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was reviewed by each participating organizations individual Institutional Review Board and found to be exempt. A waiver of informed consent and HIPAA authorization was completed at each site.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request from the authors. Such requests will be considered by a committee consisting of the investigators. Data will be made available pursuant to appropriate data use agreements.